X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with GSK Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs GSK PHARMA - Comparison Results

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA GSK PHARMA AJANTA PHARMA/
GSK PHARMA
 
P/E (TTM) x 24.9 63.0 39.6% View Chart
P/BV x 10.3 10.1 101.6% View Chart
Dividend Yield % 0.6 1.3 46.7%  

Financials

 AJANTA PHARMA   GSK PHARMA
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
GSK PHARMA
Mar-17
AJANTA PHARMA/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,7203,838 44.8%   
Low Rs1,1032,637 41.8%   
Sales per share (Unadj.) Rs194.6354.2 54.9%  
Earnings per share (Unadj.) Rs45.239.8 113.7%  
Cash flow per share (Unadj.) Rs50.342.9 117.3%  
Dividends per share (Unadj.) Rs8.0030.00 26.7%  
Dividend yield (eoy) %0.60.9 61.2%  
Book value per share (Unadj.) Rs132.0236.9 55.7%  
Shares outstanding (eoy) m88.7784.70 104.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.39.1 79.4%   
Avg P/E ratio x31.281.4 38.3%  
P/CF ratio (eoy) x28.175.5 37.2%  
Price / Book Value ratio x10.713.7 78.2%  
Dividend payout %17.775.4 23.4%   
Avg Mkt Cap Rs m125,299274,216 45.7%   
No. of employees `000NA4.7 0.0%   
Total wages/salary Rs m2,5704,830 53.2%   
Avg. sales/employee Rs ThNM6,387.0-  
Avg. wages/employee Rs ThNM1,028.3-  
Avg. net profit/employee Rs ThNM717.1-  
INCOME DATA
Net Sales Rs m17,27530,000 57.6%  
Other income Rs m166728 22.8%   
Total revenues Rs m17,44230,728 56.8%   
Gross profit Rs m5,8074,190 138.6%  
Depreciation Rs m451263 171.3%   
Interest Rs m490-   
Profit before tax Rs m5,4744,655 117.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0457 0.0%   
Tax Rs m1,4601,744 83.7%   
Profit after tax Rs m4,0143,368 119.2%  
Gross profit margin %33.614.0 240.7%  
Effective tax rate %26.737.5 71.2%   
Net profit margin %23.211.2 207.0%  
BALANCE SHEET DATA
Current assets Rs m7,63916,742 45.6%   
Current liabilities Rs m2,7157,202 37.7%   
Net working cap to sales %28.531.8 89.6%  
Current ratio x2.82.3 121.0%  
Inventory Days Days4352 83.4%  
Debtors Days Days7921 378.6%  
Net fixed assets Rs m6,9148,635 80.1%   
Share capital Rs m177847 20.9%   
"Free" reserves Rs m11,44219,222 59.5%   
Net worth Rs m11,72120,069 58.4%   
Long term debt Rs m14910 1,487.0%   
Total assets Rs m14,81430,038 49.3%  
Interest coverage x112.9NM-  
Debt to equity ratio x00 2,546.1%  
Sales to assets ratio x1.21.0 116.8%   
Return on assets %27.411.2 244.6%  
Return on equity %34.216.8 204.1%  
Return on capital %46.525.5 182.8%  
Exports to sales %55.10-   
Imports to sales %6.00-   
Exports (fob) Rs m9,527NA-   
Imports (cif) Rs m1,038NA-   
Fx inflow Rs m10,422528 1,973.8%   
Fx outflow Rs m1,6787,193 23.3%   
Net fx Rs m8,744-6,665 -131.2%   
CASH FLOW
From Operations Rs m3,2642,360 138.3%  
From Investments Rs m-2,0933,008 -69.6%  
From Financial Activity Rs m-1,186-5,108 23.2%  
Net Cashflow Rs m-15260 -5.7%  

Share Holding

Indian Promoters % 73.8 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 1.6 10.2 15.2%  
FIIs % 7.6 23.8 31.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 15.4 110.4%  
Shareholders   20,968 102,036 20.5%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   FDC LTD.  UNICHEM LAB  DR. REDDYS LAB  DIVIS LABORATORIES  ALEMBIC LTD  

Compare AJANTA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Feb 23, 2018 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 5-YR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS